|
| Press Releases |
|
 |
|
| Thursday, June 16, 2016 |
|
|
Eisai Launches New Oral Suspension Formulation for Antiepileptic Drug Fycompa (Perampanel) in the United States |
| Eisai Co., Ltd. announced today that it has launched Fycompa (perampanel) Oral Suspension, a new formulation of its in-house-discovered antiepileptic drug (AED) Fycompa, in the United States. more info >> |
|
| Friday, June 3, 2016 |
|
|
Eisai Inc. Enters Into Collaboration Agreement to Co-Promote Eisai's Anticancer Agent Lenvima in Combination with Evorolimus as Treatment for Advanced Renal Cell Carcinoma in the United States |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into an agreement with Novartis Pharmaceuticals Corporation, a U.S. affiliate of Novartis AG, to collaborate on commercial and medical affairs activities for Eisai's in-house developed novel anticancer agent Lenvima and the anticancer agent everolimus in the United States. more info >> |
|
| Wednesday, June 1, 2016 |
|
|
AbbVie and Eisai Subsidiary EA Pharma Commence Co-promotion of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Field of Gastrointestinal Disease |
| AbbVie GK, Eisai Co., Ltd. and its subsidiary EA Pharma Co., Ltd., announced that EA Pharma and AbbVie will commence the co-promotion of fully human anti-TNF-alpha monoclonal antibody HUMIRA for indications in the field of gastrointestinal disease (ulcerative colitis, Crohn's disease, intestinal Behcet's disease) as of today. more info >> |
|
| Wednesday, May 25, 2016 |
|
|
Eisai to Launch In-House Developed Antiepileptic Drug Fycompa (Perampanel Hydrate) |
| Eisai Co., Ltd. announced today that it will launch its in-house-discovered antiepileptic drug (AED) Fycompa Tablets 2 mg and 4 mg (perampanel hydrate) as an adjunctive therapy for partial-onset seizures (including secondarily generalized seizures) or primary generalized tonic-clonic seizures in patients with epilepsy showing inadequate response to other AEDs in Japan on May 26, 2016. more info >> |
|
| Tuesday, May 24, 2016 |
|
|
Eisai to Present New Research on Oncology Products and Pipeline at 52nd Asco Annual Meeting |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and Lenvima will be presented during the 52nd Annual Meeting of the American Society of Clinical Oncology. more info >> |
|
| Monday, May 16, 2016 |
|
|
U.S. FDA Approves Additional Indication for Eisai's Anticancer Agent Lenvima in Combination with Everolimus as Treatment for Advanced Renal Cell Carcinoma |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. more info >> |
|
| Thursday, April 14, 2016 |
|
|
Aricept Approved in the Philippines for New Indication as Treatment for Dementia with Lewy Bodies |
| Eisai Co., Ltd. announced today that its subsidiary in the Philippines, HI-Eisai Pharmaceutical Inc., has received approval for a new indication for the symptomatic treatment of dementia with Lewy bodies (DLB) for anti-Alzheimer's agent Aricept (donepezil hydrochloride) in the Philippines, and has commenced information provision activities. more info >> |
|
| Tuesday, April 5, 2016 |
|
|
Eisai Receives Positive CHMP Opinion on New Indicator for Anticancer Agent Halaven for Treatment of Advanced Liposarcoma |
| Eisai Co., Ltd. announced today that its European regional headquarters Eisai Europe Ltd. has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent Halaven (eribulin mesylate) for treatment of adult patients with unresectable liposarcomas. more info >> |
|
| Thursday, March 31, 2016 |
|
|
Eisai Transfer the Rights to Investigational Anticancer Agent E7777 for European, U.S and Certain Emerging Markets to Dr. Reddy's Laboratories |
| Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the exclusive worldwide development and marketing rights (excluding Japan and Asia) for its investigational anticancer agent E7777 to Dr. Reddy's Laboratories Ltd. more info >> |
|
| Wednesday, March 30, 2016 |
|
|
Eisai Co., Ltd. and Ajinomoto Co., Inc. Announce Establishment of Gastrointestinal Specialty Pharma EA Pharma Co., Ltd. |
| Eisai Co., Ltd. and Ajinomoto Co., Inc. announced today that based on the integration agreement signed and announced on October 15, 2015, the gastrointestinal specialty pharma EA Pharma Co., Ltd. will be established through the splitting off of a portion of Eisai's gastrointestinal disease treatment. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Four HK designer labels shine at London Fashion Week
Feb 22, 2025 22:56 HKT/SGT
|
|
|
Dollamur Announces United World Wrestling Approval Through 2028
Feb 22, 2025 22:54 HKT/SGT
|
|
|
Yashaa Global Capital Secures Financial Services Permission to Establish a Global Sports VC Fund
Feb 22, 2025 20:11 HKT/SGT
|
|
|
AsiaMedic and Sunway launch new Medical Diagnostic Imaging Centre in Novena 
Feb 22, 2025 18:00 HKT/SGT
|
|
|
Soligenix's Leadership Aims to Drive Growth in Rare Disease Markets in 2025 and 2026
Feb 22, 2025 4:50 JST
|
|
|
Alexis Mc Allister Announces as Jeton's Latest Brand Ambassador
Feb 21, 2025 23:00 HKT/SGT
|
|
|
NaaS Technology Launches $10 Million Share Repurchase Plan Boosting Market Confidence
Feb 21, 2025 21:09 HKT/SGT
|
|
|
Honda Receives Highest Ranking of 3 Stars as Part of FIA Road Safety Index, Tool for Organizations and Companies to Measure Their Road Safety Footprint
Feb 21, 2025 19:40 JST
|
|
|
Carl Zeiss Honors EuroEyes International for Exceptional Milestone in AT LISA(R) Trifocal Lens Implantations
Feb 21, 2025 18:29 HKT/SGT
|
|
|
Honda Partners with United Nations Road Safety Fund (UNRSF) to Work Toward Reduction of Fatalities from Traffic Collisions
Feb 21, 2025 19:11 JST
|
|
|
Mitsubishi Logistics Corporation, Mitsubishi Corporation, and Yourstand Inc. Advancing Completely CO2-Free Electrification of Pharmaceutical Transportation
Feb 21, 2025 15:01 JST
|
|
|
NEC Innovation Challenge awards Canada's Prevu3D Inc. with the NEC Award and NOFF Award
Feb 21, 2025 14:39 JST
|
|
|
NEC Develops Near Real-time RIC for High Performance 5G vRAN
Feb 21, 2025 12:00 JST
|
|
|
Igloo kicks off 2025 with Multi-market Partnership Wins and Chief Distribution Officer Appointment
Feb 21, 2025 09:00 HKT/SGT
|
|
|
Giftify, Inc. Announces Smart Savings Solution for Popular GLP-1 Diabetes and Weight Loss Medications
Feb 21, 2025 08:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
